AlphAIalphai — Financial news for AI agents
theglobeandmail.comAUG 272 min read$SPRB

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts from H.C. Wainwright and Deutsche Bank maintained Buy ratings on Spruce Biosciences (SPRB), PDS Biotechnology (PDSB), and BioNTech SE (BNTX). Price targets set at $150, $7, and $140 respectively. Current share prices are $63.40, $0.22, and $114.05. Analyst consensus for SPR and BNTX is Strong Buy, with upsides of 160.4% and 12.9% respectively.

Original reporting
theglobeandmail.com
Published Aug 27, 2026, 10:28 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 3:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Wall Street Analysts Are Bullish on Top Healthcare Picks — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$SPRBBullishMed
01

Why it matters

The upgrades could prompt short-term buying pressure, especially in the micro‑cap names with large upside percentages.

02

Market read

Analyst upgrades provide fresh actionable data for traders focusing on biotech stocks.

03

What to watch

Potential regulatory or clinical trial setbacks could negate upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Three analysts issued fresh Buy ratings and price targets for Spruce Biosciences, PDS Biotechnology, and BioNTech.

Company-level read

Ticker impact

$SPRBBullishMedium confidence
Context

Analyst Ram Selvaraju maintained a Buy rating and set a $150 price target for Spruce Biosciences.

Expected impact

Short-term price pressure upward as investors react to the new target.

Evidence & confidence

Buy rating and higher target may attract buying interest.

$PDSBBullishMedium confidence
Context

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and set a $7 price target for PDS Biotechnology.

Expected impact

Sharp price rally possible if market participants notice the target.

Evidence & confidence

Large upside relative to current price could trigger speculative buying.

$BNTXBullishMedium confidence
Context

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating and set a $140 price target for BioNTech SE.

Expected impact

Modest upward pressure as investors adjust expectations.

Evidence & confidence

Buy rating with a modest premium may lead to incremental buying.

Market effects

Sector

Analyst bullishness may lift sentiment across the healthcare sector.

Regional

U.S. healthcare equities could see modest gains.

Global

Limited to investors tracking biotech and pharma stocks.

Counterpoint

What could challenge this read

Price targets may be overly optimistic given recent market volatility.

Key entities

  • analyst
    Ram Selvaraju

    H.C. Wainwright analyst covering Spruce Biosciences.

  • analyst
    Joseph Pantginis

    H.C. Wainwright analyst covering PDS Biotechnology.

  • analyst
    Emmanuel Papadakis

    Deutsche Bank analyst covering BioNTech.

Read at source← All news

Related articles

SEP 4
$PFEHighAI 8/10

19 vaccine approved by US FDA

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

pmlive.com2 min
SEP 4
$MRNAHighAI 8/10

Moderna Already Won Round One—or Is BioNTech the Smarter Bet?

Moderna (MRNA) and BioNTech (BNTX) are focusing on cancer vaccines post-pandemic. Moderna's cancer vaccine showed strong Phase 3 results, boosting its shares. BioNTech's pumitamig, in development with Bristol Myers Squibb, aims to challenge Merck's Keytruda. BioNTech's market cap is $26B, while Moderna's is $60B. Both are valued on pipeline progress, with Moderna offering near-term certainty and BioNTech potential upside if pumitamig succeeds.

nai500.com3 min
AUG 31
$BNTXLow

Autogene Cevumeran Trial Terminated in Resected Colorectal Cancer

BioNTech terminated its phase 2 BNT122-01 trial of autogene cevumeran in colorectal cancer due to a DSMB recommendation, citing an imbalance in overall survival and unlikely efficacy. The trial tested the mRNA immunotherapy as a monotherapy. No new safety concerns were identified. The decision does not impact other trials, including a phase 2 study in pancreatic cancer.

cancernetwork.com2 min
AUG 31
$BNTXMedAI 8/10

BioNTech Terminates Phase II Clinical Trial for Cevumeran

BioNTech and Genentech terminated a Phase II trial for autogene Cevumeran, an mRNA cancer immunotherapy, in colorectal cancer patients due to efficacy concerns. The Data Safety Monitoring Board recommended termination after finding no significant efficacy. The decision does not affect another ongoing trial for pancreatic cancer. BioNTech plans to analyze the data and share findings with the scientific community.

pharmexec.com6 min
AUG 29
$BNTXMedAI 8/10

BioNTech Stock Tumbles 10% After Colorectal Cancer Vaccine Trial Fails

BioNTech's stock dropped 10% after terminating a clinical trial for a colorectal cancer vaccine, impacting its oncology pipeline and raising doubts about its mRNA cancer treatment strategy. Moderna also fell 6%, while Pfizer remained stable. The setback highlights the risks in experimental cancer programs and may lead to a repricing of BioNTech's pipeline risk.

beijingtimes.com2 min